Skip to content
Study details
Enrolling now

Dexrazoxane Hydrochloride to Prevent Heart Problems from Chemotherapy

M.D. Anderson Cancer Center
NCT IDNCT03589729ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 9.3 years

Ages

12+

Locations

1 site in TX

What this study is about

This trial is testing whether dexrazoxane hydrochloride can help prevent heart problems caused by chemotherapy in people with blood cancers. The treatment involves taking dexrazoxane hydrochloride along with other chemotherapy drugs like cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cladribine
  • 2.Take Cytarabine
  • 3.Take Dexrazoxane Hydrochloride
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cladribine, cytarabine, Cardiovascular Agent [TC] (Chelating Activity), gemtuzumab ozogamicin, idarubicin

Drug routes

injection, intravenous, injection (Injection), infusion

Endpoints

Secondary: Complete remission (CR) /complete remission with incomplete blood count recovery (CRi) rates (Cohorts 1-3), Event-free survival (Cohorts 1-3), Incidence of adverse events, Incidence of cardiac symptoms, Overall response (Cohorts 1-3), Overall survival (Cohorts 1-3), Recurrence-free survival

Body systems

Oncology, Musculoskeletal